Bio-Rad Labs (NYSE: BIO) reported Q4 EPS of ($0.70), which does not compare to the analyst estimate of $1.03. Revenue for the quarter came in at $571.5 million versus the consensus estimate of $570.1 million.

For earnings history and earnings-related data on Bio-Rad Labs (BIO) click here.